Moleculin Biotech announced progress in its Phase 2/3 MIRACLE trial testing Annamycin combined with high-dose cytarabine for relapsed or refractory acute myeloid leukemia (AML). Enrollment in Part A is complete, with encouraging interim efficacy and cardiac safety results. Full data from 90 patients in Part A is expected in Q1 2027, guiding the next pivotal Part B trial phase. Annamycin aims to overcome treatment resistance and reduce heart toxicity compared to standard anthracyclines, with potential use in other cancers.
Moleculin's recent update on its Annamycin MIRACLE trial provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:03 WIB: of 150 priced US health stocks, 81 rose and 62 fell. Notable movers include HRTX at USD 0.36 with a -2.63% change and 42% sell order activity, SNY at USD 40.57 up 2.53%, and CRSP at USD 48.95 down 2.18% with 83% buy order activity.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
